Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Shanghai Stock Exchange  >  Shanghai Fosun Pharmaceutical Group Co., Ltd.    600196   CNE000000X38

SHANGHAI FOSUN PHARMACEUTICAL GROUP CO.,

(600196)
  Report
End-of-day quote. End-of-day quote Shanghai Stock Exchange - 08/07
69.7 CNY   -7.80%
08/07AstraZeneca Sets Deal in China Market -- WSJ
DJ
08/06AstraZeneca Strikes Deal to Produce Covid-19 Vaccine for China
DJ
08/06AstraZeneca in first COVID-19 vaccine deal with Chinese company
RE
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
Strengths
  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • Within the weekly time frame the stock shows a bullish technical configuration above the support level at 42.08 CNY
Weaknesses
  • Stock prices approach a strong long-term resistance in weekly data at CNY 70.58.
  • Technically, the stock approaches a strong medium-term resistance at CNY 75.6.
  • The group shows a rather high level of debt in proportion to its EBITDA.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
  • The company's enterprise value to sales, at 5.93 times its current sales, is high.
  • With an expected P/E ratio at 49.96 and 42.19 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
  • The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
Ratings chart
Sector Generic Pharmaceuticals
1st jan.Capitalisation (M$)Investor Rating
SHANGHAI FOSUN PHARMACEUTIC..162.03%22 805
OTSUKA HOLDINGS CO., LTD.-5.82%23 562
SUN PHARMACEUTICAL INDUSTRI..21.59%16 821
ONO PHARMACEUTICAL CO., LTD..21.14%14 293
DIVI'S LABORATORIES LIMITED50.87%9 854
ZHEJIANG NHU COMPANY LTD.27.56%9 149
CIPLA LIMITED52.37%7 831
ASYMCHEM LABORATORIES (TIAN..67.58%7 205
THE MEDICINES COMPANY-0.05%6 788
-
CADILA HEALTHCARE LIMITED53.72%5 334
SHENZHEN SALUBRIS PHARMACEU..72.97%5 122
TAISHO PHARMACEUTICAL HOLDI..-23.67%4 668
SICHUAN KELUN PHARMACEUTICA..-4.68%4 623
RICHTER GEDEON VEGYÉSZETI G..11.46%4 524
HANMI PHARM. CO., LTD.19.22%3 497
ASPEN PHARMACARE HOLDINGS L..12.04%3 463
More Results
Financials
Sales 2020 32 396 M 4 650 M 4 650 M
Net income 2020 3 545 M 509 M 509 M
Net Debt 2020 13 549 M 1 945 M 1 945 M
P/E ratio 2020 50,0x
Yield 2020 0,59%
Capitalization 159 B 22 805 M 22 807 M
EV / Sales 2020 5,32x
EV / Sales 2021 4,53x
Nbr of Employees 31 370
Free-Float 62,3%
Upcoming event on SHANGHAI FOSUN PHARMACEUTI
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes